Genzyme Receives FDA Approval for Lumizyme for Pompe Disease
- Details
- Category: Genzyme
Genzyme Corporation (Nasdaq: GENZ) announced that the FDA has granted U.S. marketing approval for Lumizyme™ (alglucosidase alfa), produced at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium.
European Medicines Agency maintains position on the continued use of Rotarix
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) confirmed that following a meeting of the Committee for Medicinal Products for Human Use (CHMP), the European Medicines Agency (EMA) has maintained its position that there is no evidence that the presence of porcine circovirus (PCV) in Rotarix™ presents a risk to public health and that there is no need to restrict its use in the European Union.
Ranibizumab significantly more effective than standard of care in treating vision loss due to DME
- Details
- Category: Novartis
First results of the RESTORE Phase III study show that ranibizumab is significantly more effective than laser treatment, the current standard of care, at treating visual impairment due to diabetic macular edema (DME), a serious complication of diabetes[1].
Abbott to Become No. 1 Pharmaceutical Company in India
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced a definitive agreement with Piramal Healthcare Limited to acquire full ownership of Piramal's Healthcare Solutions business (Domestic Formulations), a leader in the Indian branded generics market, for an up-front payment of $2.12 billion, plus $400 million annually for the next four years, giving Abbott the No. 1 position in the Indian pharmaceutical market.
Pfizer Global Manufacturing Announces Plans to Reconfigure its Global Plant Network
- Details
- Category: Pfizer
Pfizer Global Manufacturing announced plans to reconfigure its worldwide plant network to create a fully aligned manufacturing and supply organization from the combined networks of Pfizer and Wyeth.
Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
- Details
- Category: Financial
Astellas Pharma Inc. (TSE: 4503), a global pharmaceutical company, and OSI Pharmaceuticals, Inc. (Nasdaq: OSIP), a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing medical needs in oncology, diabetes and obesity, have entered into a definitive merger agreement under which Astellas will acquire OSI.
Sanofi-aventis Announces the Creation of the "Sanofi Espoir" Corporate Foundation
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced the creation of the Sanofi Espoir Corporate Foundation, dedicated to implementing health and solidarity programs worldwide.
More Pharma News ...
- Forest Laboratories and Nycomed Receive Complete Response Letter for Roflumilast
- Bayer Schering Pharma Enhances U.S. Research Strategy with New Innovation Center
- Positive pivotal results on escitalopram in Japan
- Covex S.A. creates 2000 jobs with the onset of a new agroindustrial project in Latin America
- Bayer receives approval for its new oral contraceptive in the U.S.
- RA.com Features Interactive Resource to Help People Living with Rheumatoid Arthritis
- New study results on Dulcolax® confirm efficacy and safety